Kidney function estimators for drug dose adjustment of direct oral anticoagulants in older adults with atrial fibrillation

نویسندگان

چکیده

Abstract Background The Cockcroft-Gault equation (CrClC-G) is recommended for dose adjustment of direct oral anticoagulant drugs (DOACs) to kidney function. We aimed assess whether defining DOACs appropriateness according various function estimators changed the associations between and adverse events in older adults with atrial fibrillation (AF). Methods Participants Berlin Initiative Study AF treated were included. investigated CrClC-G estimated glomerular filtration rate (eGFR) using CKD-EPI EKFC equations based on creatinine and/or cystatin C. Marginal structural Cox models yielded confounder-adjusted hazard ratios risk mortality, thromboembolism, bleeding associated status. Results 224 patients included analysis (median age 87 years). Using CrClC-G, 154 (69%) had appropriate DOACs, 52 (23%) underdosed, 18 (8%) overdosed. During a 39-month median follow-up period, 109 (14.9/100 person-years) participants died, 25 (3.6/100 experienced 60 (9.8/100 bleeding. Dose status was not mortality independent equation. Underdose lower all equations, compared group. In discrepancies eGFR occurrence endpoints did differ having or eGFR. Conclusions AF, association when Our results suggest that are inferior within this context.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients

BACKGROUND Direct oral anticoagulants (DOACs) have been developed for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). We conducted a retrospective cohort study of patients with NVAF who were newly treated with DOACs in a real-world clinical setting. METHODS We retrospectively analyzed patients with NVAF newly treated with one of three DOACs-dabigatran, rivaroxaban,...

متن کامل

New oral anticoagulants for atrial fibrillation.

Case 1A: A 68-year-old man with a past medical history of atrial fibrillation (AF), hypertension, and type 2 diabetes mellitus has been on anticoagulation therapy with warfarin for 6 years. The patient’s target international normalized ratio (INR) is 2.0 to 3.0. The patient has been managed by a pharmacist-run anticoagulation clinic, and his recent warfarin doses and INR values are shown in Tab...

متن کامل

New Oral Anticoagulants for Atrial Fibrillation

ABSTRACT Atrial fibrillation (AF) is the most common cardiac arrhythmia in the U.S. Anticoagulation is recommended for stroke prevention in AF patients with intermediate-to-high stroke risk (i.e., patients with a CHADS2 score of 1 or greater). Warfarin was previously the only option for oral anticoagulation in these patients, but three new oral anticoagulants have become available as alternativ...

متن کامل

New oral anticoagulants in atrial fibrillation forever?

A trial fibrillation is the most common chronic cardiac arrhythmia in clinical cardiology. It affects ≈1% of the population, and, of individuals >80 years of age, ≈10% have this rhythm disturbance. Owing to the loss of the atrial contribution to ventricular filling, left ventricular function is diminished resulting in a propensity to heart failure, fatigue, and disability. Furthermore, the sens...

متن کامل

New oral anticoagulants in atrial fibrillation.

Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K antagonists (VKAs; oral anticoagulants), including warfarin, are the only approved antithrombotic therapies for stroke prevention in patients with AF. Although effective, VKAs have unpredictable pharmacological effects, requiring regular coagulation monitoring and dos...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Ndt Plus

سال: 2023

ISSN: ['2048-8513', '2048-8505']

DOI: https://doi.org/10.1093/ckj/sfad218